The contract, which envisages the merger of Bulgarian Rose-Sevtopolis into the structure of Sopharma, was signed on October 29 and was filed with the country’s financial regulator, Sopharma said in a statement on the Sofia bourse.
Bulgarian Rose-Sevtopolis, previously 49.99%-owned by blue-chip Sopharma, produces substances used in drugs which Sopharma exports mainly to Ukraine and Russia.